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1.1 Anatomy and histology of the prostate 
  
The prostate is a male sexual organ, which is a chestnut-shaped gland 
located directly below the apex of the bladder (as shown in figure 1), with 
the urethra passing through inside, and seminal vesicles accompanying 
outside above the back in humans [1-3].  
 
In primates, the prostate surrounds parts of the urethra. The segment of the 
urethra surrounded by the prostate is termed the prostatic urethra or the 
proximal urethra. A pair of ejaculatory ducts passes through the prostate 
and has an opening in the prostatic urethra along with the prostatic ducts 
(as shown in figure 1) [2, 3].  
 
The prostate can be divided into the anterior fibromuscular stroma and 
three glandular zones: the central zone, the transition zone and the 
peripheral zone. In the normal state, the peripheral zone constitutes 70% of 





transition zone 5%. There is a fibromuscular band surrounding the prostate, 
with the term “prostate capsule” referring to it [3, 4]. 
 
 
Figure 1. Sagittal plane of human prostate. The prostate is located 
below the bladder. The urethra and the urine flow run through the prostate. 
The ejaculatory ducts pass through the prostate and open in the prostatic 
urethra (The figure is adapted from “Sathianathen, N. J., Konety, B. R., 
Crook, J., Saad, F., & Lawrentschuk, N. (2018). Landmarks in prostate 
cancer. Nature Reviews Urology.”). 
 
The glandular prostate contains ducts and acini, which are similar in cell 
constitution and morphological pattern. Among the cells that form ducts 
and acini, glandular epithelial cells are androgen-receptor-rich secretive 
cells which synthesize prostatic fluid [5]. Basal cells are not as 





and are considered to haver differentiation potential [2, 5]. Endocrine 
-paracrine cells are not well known, and can only be shown by ancillary 
techniques. They are assumed to mediate growth and function of the 
prostate [5]. 
 
The stroma lies between the glands, contributing to about half of the 
prostate volume. The fibromuscular stroma consists of abundant smooth 
muscle cells distributed randomly in direction surrounding the glands, and 
is separated by elastic fibers [2]. 
 
1.2 Physiology of the prostate  
  
1.2.1 Function  
As an exocrine gland, the prostate secretes the milky fluid called prostatic 
fluid, serving to nourish and protect sperm. The prostate is an organ for 
balanced production, storage, composition, and pulse-triggered release of 
its product, owing to its substantial architecture containing acini and 
smooth muscle. The prostatic fluid is extremely abundant in Zn
2+
, citrate 
and kallikreins [6]. The concentration of citrate in the prostatic fluid is 







 in prostatic fluid is achieved by Zn
2+
 transporters, 
which makes the prostate as the organ or body compartment with the 
highest Zn
2+
 concentration. [7]. Citrate is crucial for adenosine 
5’-triphosphate (ATP) formation of sperm [9], while Zn
2+
 can facilitate 
citrate formation. Zn
2+
, citrate and kallikreins together participate in 
promoting fertility by controlling the molecular function of the sperm in 
the ejaculatory process like liquefication and motility [8]. 
 
For healthy men, the prostate smooth muscle contracts during the 
ejaculatory process to press the stored prostatic fluid out into the urethra, 
while in patients with benign prostatic hyperplasia (BPH), the smooth 
muscle tone increases and contributes to dynamic obstruction of the 
bladder outlet [10]. In normal conditions, the fibromuscular band can 
confront the pressure from the urethra. In morbid conditions, the band 
restricts carcinoma from invasion and metastasis, but it promotes the 
mechanical obstruction by facilitating the pressure increase to the urethra 
in the prostate when the prostate gets enlarged [2, 4, 11, 12].  
 
1.2.2 Hormonal regulation and nerve innervation 
The development and growth of the prostate are regulated by androgen 





(DHT) is synthesized from testosterone by 5α-reductase in the prostate, 
and it is strictly essential for prostate formation and development from the 
early beginning since the embryonic period [13]. Lack of DHT causes 
prostate absence or dysplasia. Under the continuous effect of DHT, the 
prostate grows and transforms into the adult phenotype by 21-30 years old 
[14, 15]. Then, the prostate continues to grow slowly starting at the normal 
average weight of 20 g. When men come to an age of 51-60 years old, 50 
percent have an enlarged prostate weighing 33 g on average [14] 
 
The secretory function is also highly dependent on DHT, and without DHT 
the prostatic function is expected to get lost. Ageing is paralleled by 
reduced testosterone and also intraprostatic DHT, which damages the 
ability of prostate epithelial cells to concentrate Zn
2+
, and to synthesize 
secretive citrate and kallikreins, finally compromising fertility [8]. Other 
hormones also have roles in regulating the secretion function. Citrate 
production, for instance, receives regulation by DHT, prolactin [7] and 
estrogens [6].  
 
Other evidence shows that the growth and secretion of the prostate can also 
be regulated neurogenicallly. The prostate is mainly innervated with 





growth via α1 and β2 adrenergic receptors, while cholinergic [16] and 
β-adrenergic nerves innervate glandular epithelial parts with the potential 
to mediate secretion [17] [18].  
 
One of the main effects of the nerve innervation is to mediate smooth 
muscle contraction and relaxation. Prostatic smooth muscle receives 
massive noradrenergic innervation, which mainly mediate contraction [19]. 
Nitric oxide (NO) and parasympathetic nerves are responsible for smooth 
muscle relaxation [18] [20]. Acetylcholine, NO and neurotransmitters like 
adenine nucleotides and nucleosides, opioids, neuropeptide Y (NPY) and 
vasoactive intestinal peptide [21] may act as co-transmitters or modulators 
in autonomic neurotransmission supplying prostate stroma and smooth 
muscle tone [19]. 
 
Apart from adrenergic neurotransmission, some hormonal or other 
non-adrenergic agonists including endothelins and thromboxane A2 
(TXA2) induce prostate smooth muscle contraction, and contribute to 






1.3 Benign prostatic hyperplasia 
  
Benign prostatic hyperplasia (BPH) is a result of hyperplastic growth of 
the stroma and glandular epithelium, and occurs most obviously in the 
transition zone [24]. Technically, BPH is only the histologic condition able 
to result in benign prostatic enlargement (BPE) [25]. Bladder outlet 
obstruction (BOO) is the clinical condition, which is often a result of 
benign prostatic obstruction (BPO) caused by BPE, considering the urine 
flow from the bladder going through the prostatic urethra [26]. BOO can be 
aggravated by the dynamic factor resulting from increased tone of prostate 
smooth muscle [10]. 
 
1.3.1 Epidemiology and etiology  
BPH is related to ageing. Until an age of 25–30 years, the prostate enlarges 
to a “normal” weight of about 20 g. From this age, prostate growth is 
stopped or only slow, until age-related BPH is beginning. Thus, the 
Olmstead County Study reported longitudinal data suggesting an annual 
prostate growth rate of 1.6 % as measured by transurethral ultrasonography 
[27]. Symptomatic BPH usually emerged after 40 years. The prevalence of 





60 years old, and more than 80 % among men of 70 to 79 years old [27]. 
DHT was assumed to be the continuous stimulating factor resulting in BPH 
progression related to aging, with the risk of BPH for men who have the 
highest DHT level nearly 3-fold higher than men with lowest levels [28]. 
However, recent research reported that estrogen also contributes the 
growth of prostate when men get aged [6]. 
 
Other studies have also demonstrated that genetic factors may also be 
involved in BPH. A study took the youngest quartile (< 64 years old) with 
a resected prostate greater than 37 cm
3
 from patients who were under 
prostatectomies for BPH as probands, and found the risk of brothers of the 
probands is 6 times higher than the controls [29]. Familial BPH patients 
have been found to had larger prostate volume and normal serum androgen 
levels, which indicated that the genetic factor may be involved in prostate 
growth independently from androgen [30]. Ethnicity differences may 
further explain the genetic factor. Black men and Asian men were found to 
be less likely to have BPH than white [31, 32]. Caucasian from southern 
Europe have the highest risk [31].  
 
Apart from those unchangeable or inherited factors, some risk factors can 





revealed to profoundly increase the risk of BPH [27]. It was shown that 
physical exercise decreased the risks of BPH profoundly [33, 34], and an 
unhealthy diet contributed to BPH in multiple patterns [35]. 
 
Various studies showed that systemic diseases can affect the blood supply 
of the prostate. Theses diseases are related to BPH, and include 
cardiovascular diseases like systemic atherosclerosis and metabolic 
diseases like diabetes [36, 37]. The pathophysiology behind it may concern 
increased growth factors under the hypoxic condition [38]. Studies also 
revealed that metabolic diseases can cause autonomic nerve disorder and 
contribute to prostate growth via corresponding receptors [39]. In patients 
with metabolic syndrome, related regulatory molecules can directly result 
in BPH [40, 41].  
 
Local conditions like prostatic inflammation are also considered to be a 
factor for BPH development. Under consistent stimulation of 
inflammatory cytokines, epithelial cells are driven to grow in the chronic 







BPH is related to clinically relevant complications, including urinary 
retention, haematuria, urinary tract infection, bladder calculi, 
hydronephrosis, incontinence [3, 43, 44]. Complications are important 
indexes for BPH progression and likely indications for surgery [3, 43-45]. 
 
Urinary retention (UR) consists of acute UR (AUR), chronic UR (CUR) or 
acute on chronic UR. AUR has a sudden onset and could be extremely 
painful [46], while CUR is usually without pain and featured by increased 
residual urine after voiding, which can usually palpable or percussible. 
AUR may also present in CUR patients [47].  
 
Haematuria usually results from the friable hypervascularity in BPH [48]. 
Medication for BPH like finasteride may decrease angiogenesis and 
improve haematuria [48]. Haematuria also results from infection and 
calculi. 
 
Urinary tract infection (UTI) and bladder calculi occur when BPH patients 
can not sufficiently empty the bladder. This provides an environment for 
bacteria or calculi growth. Recurrent UTI and bladder calculi are absolute 






Hydronephrosis is usually secondary to CUR in BPH, since patients with 
CUR have significantly higher bladder pressure and may finally affect the 
pressure in the renal pelvis resulting in hydronephrosis [49]. Chronic renal 
failure is the final and severest prognosis in this situation, so 
hydronephrosis is also an absolute indication for surgical intervention [3, 
49]. 
 
Incontinence may be due to overactive detrusor independent from or 
secondary to long-term BOO and CUR in BPH patients, called urgency 
incontinence. Overflow incontinence may also present in BPH patients 
with CUR [50]. 
 
1.4 Male lower urinary tract symptoms 
 
Lower urinary tract symptoms (LUTS) are a group of symptoms caused by 
various diseases, classified as voiding symptoms and storage symptoms [3, 
43]. Voiding symptoms include “hesitation, difficulty, intermittence and 
weakness of urination, and terminal dribbling”, while storage symptoms 







Causes of male LUTS are quite widespread. Problems concerning bladder 
function or its outlet may be the causes (showed in figure 2) [45]. Apart 
from the disease in the lower urinary system, the causes can also be 
non-urological diseases affecting the whole body system, which may 
include cardiovascular or respiratory system, nervous system, endocrine 
system, as well as any other conditions that would facilitate inflammation, 
cause hyperplasia of detrusor or prostate, damage the function of nerve 
innervation, or influence contraction of detrusor or the bladder 
outlet-related smooth muscle including prostate smooth muscle. For aged 







Figure 2. Causes of male LUTS. Benign prostatic obstruction is the most 
common cause of male LUTS, other urological and non-urological causes 
contribute as well. (The figure is adapted from Oelke M, Bachmann A, 
Descazeaud A, Emberton M, Gravas S, Michel MC, et al. (2013). EAU 
guidelines on the treatment and follow-up of non-neurogenic male lower 




LUTS are common in both genders especially for people older than 40 





reason for LUTS. According to statistics, LUTS affected 2.3 billion people 
worldwide in 2018, and nearly half of them were men [51]. LUTS are 
especially highly prevalent in aged men, with 70% of men ≥ 80 years 
reported LUTS and 51.6% of them reported moderate-to-severe LUTS [52, 
53]. BPH alone costs more than 180 million pounds each year in the United 
Kingdom [54] and 1.1 billion dollars in the single year of 2000 in the 
United States [55]. Among these costs, around 60% are spent for 
management of BPH complications. Quality of life (QOL) in male LUTS 
patients has been decreased due to bothersome symptoms and the fact that 
LUTS patients are also related to anxiety, depression, and unsatisfied 
sexual life. QOL of partners of male LUTS patients has been compromised 
as well [27]. 
 
1.4.3 The role of BPH in LUTS 
Enlargement of the prostate due to BPH causes increased resistance to 
urinary flow, so that mechanical obstruction of the bladder outlet due to 
increased prostate size contributes to voiding symptoms and to increased 
postvoid urine volume [3, 45]. Although BPH mainly starts in the 
transition zone and the degree of compression on the prostatic urethra is 
the most crucial, total prostate size is still an important index. Researches 





men with a prostate volume of 40.1-80 ml are more likely to develop 
bothersome and progressive LUTS in the future even with mild or no 
LUTS than men with a prostate volume below 40 ml. Larger prostates 
correlated with increased risk of acute urinary retention and are more likely 
to progress to surgery [49]. 
 
Enlarged prostates can weaken urine flow by compressing the urethra, 
which causes voiding (obstructive) symptoms, consisting of hesitancy, 
weakness, straining, prolonged micturition, incomplete emptying, 
dribbling, etc [44, 45]. At the early stage of BPH, the detrusor gets stronger 
and the bladder wall gets hyperplasic to compensate for the obstruction of 
the bladder outlet. Eventually, the detrusor loses the ability to confront the 
pressure, and then becomes weak and unable to empty itself, which is 
called decompensation. Increased postvoid urine volume may result in 
detrusor hyperplasia, which in turn may cause storage (irritative) 
symptoms including frequency, urgency, urge incontinence and nocturia [3, 
44]. An enlarged prostate can also directly compress the triangle district in 
the bladder, contributing to the irritative symptom [49]. If the condition 
continues to progress, the patient will suffer from urinary incontinence or 
other complications like hydronephrosis. What should be pointed out is 
that BPH causes bladder obstruction by not only mechanical compression 





increased prostate smooth muscle tone [27]. 
 
1.4.4 Current medical treatment of male LUTS 
The current medicational treatment of male LUTS [44] follows the strategy 













Figure 3. Non-surgical treatment algorithm for male LUTS. The 
algorithm includes different LUTS occuring in men, i. e. obstructive 
(„urinary“) symptoms suggestive of BPH, and bladder-related symptoms 
including storage symptoms and nocturia. The depicted procedures are 
based on the guidelines of the European Association of Urology (EAU) for 
treatment of male LUTS [44]. 
 
Alpha1-adrenoceptor blockers 
Alpha1-(α1)-adrenergic receptors mediate prostate smooth contraction and 
contribute to basic tension of prostate smooth muscle. They are responsible 





consequently represent important determinants of bladder outlet 
obstruction. Thus, α1-blockers can theoretically relieve the resistance of 
the bladder outlet. Alpha1-selective blockers include tamsulosin, alfuzosin, 
terazosin, doxazosin and silodosin. Researches suggest that α1-blockers 
can decrease International Prostate Symptom Score (IPSS) and improve 
quality of life [56], and objectively improve urinary voiding function, i.e. 
the maximum flow rate (Qmax) [57]. Researches found that the effect of the 
α1a-adrenoceptors subtype predominates in the contraction of prostate 
smooth muscle [58]. Tamsulosin is the most commonly used medication 
for LUTS suggestive of BPH [59], and the selectivity of tamsulosin for the 
α1a subtype is tenfold higher than for the α1b subtype [60], while silodosin 
is selectively targeting on α1a. Clinical studies suggested that silodosin has 
advantages in relieving nocturia and lowering side effects outside the 
lower urinary tract compared to other α1-blockers. However, silodosin 
shows a higher risk of ejaculatory dysfunction [61].  
 
5α-reductase inhibitors  
5α-reductase inhibitors (5-ARIs) inhibit the conversion of testosterone to 
DHT. DHT has a higher affinity to androgen receptors than testosterone. 
Considering that the proliferation of prostate cells is relying on androgen, 
5-ARIs can change the natural progression of the BPH process [62]. 





α1-blockers, they can decrease the acute urinary retention rate [63]. Side 
effects may include erectile dysfunction, decreased sex drive or retrograde 
ejaculation [64]. 
 
Phosphodiesterase (PDE) inhibitors  
Currently, PDEs inhibitors are widely used in erectile dysfunction, which 
mainly target on PDE5 who degrade [65] guanosine 3', 5'-cyclic 
monophosphate (cGMP) and consequently relaxes the vascular smooth 
muscle controlling the blood flow of the corpus cavernosum. Recently, a 
PDE5 inhibitor has been approved for treatment of LUTS suggestive of 
BPH, regardless of the presence or absence of ED. PDE5 inhibitors have 
been shown to reduce prostate smooth contractions [66] and improve IPSS 
[67]. In fact, however, PDE5 inhibitors have limited effects in LUTS (i. e. 
resembling those of α1-blockers), and combination therapy with 
α1-blockers is more effective than monotherapy with PDE5 inhibitors [68, 
69]. 
 
Vasopressin analogue  
If the patient shows LUTS mainly about nocturnal polyuria, vasopressin 
analogues can be used to reduce the amount of urine produced during the 





Vasopressin analogues can only be applied for men under 65 years to 
avoid side effects like hyponatremia [70]. 
 
 
Muscarinic receptor antagonists  
Muscarinic receptor antagonists are available to treat overactive bladder 
considering that contraction of the detrusor is driven by muscarinic 
receptors[71]. They are recommended to treat storage symptoms of men 
with LUTS suggestive of BPH combined or without combination with 
medications reducing outlet obstruction [44]. Although there is a 
theoretical concern that muscarinic receptor antagonists may increase 
residual urine volume and acute urinary retention rate, clinical trials show 
relief in storage symptoms without obvious effects on voiding symptoms 
or AUR rate [39, 44, 72]. Although solifenacin is a selective antagonist for 
the subtype 3 muscarinic receptor (M3), discontinuation due to side effects 
such as dry mouth could be the critical limit of antimuscarinics. Sometimes 
a combination of antimuscarinics and salivary-gland-specific muscarinic 
agonists are needed to reduce dry mouth [44, 59].  
 
β3-adrenoceptor agonists (β3-agonists) 





and function of β3-adrenoceptors in the bladder, its agonists are assumed to 
improve OAB by relaxation of detrusor smooth muscle. Mirabegron is best 
known β3-adrenoceptor agonist used for LUTS treatment. One of the 
advantages of β3-agonists is to reduce the side effect of antimuscarinics. It 
has been revealed that the combination treatment of β3-agonists and 
half-dose antimuscarinics significantly reduced side effects compared with 
only using antimuscarinics in full dose [73]. 
 
Limitations of current medications 
Among the medical options above, α1-adrenoceptor antagonists are still the 
most important and commonly used, as they directly target prostate smooth 
muscle contraction by inhibiting α1-adrenergic receptors, and relieve the 
compression of prostatic urethra [60, 74]. Alpha1-blockers reduce the IPSS 
by 30-40% and increases of Qmax of 20-25% [75]. However, placebos cause 
improvements of IPSS by up to 34%, and increase Qmax by up to 27% [76]. 
Moreover, α1-blockers do not change the prostate volume, with limited 
evidence to prevent AUR or other severe complications [74]. Up to 69 % 
of patients may not be satisfied by treatment with α1-blockers, thus, the 
efficacy is not satisfying enough, considering the age-dependency of 
prevalence [22, 23, 77, 78]. Using 5-ARIs solely or combined with 
α1-blockers can not only improve IPSS and Qmax, but also reduces the 





unsatisfied even using a combination therapy of α1-blockers with 5-ARIs 
[79]. Side effects and unsatifying efficacy contribute together to the 
discontinuation rate of combination therapy [45].  
 
Non-adrenergic mediators induce prostate smooth muscle contraction 
apart from α1-adrenceptors and include receptors like thromboxane A2 
receptors and endothelin receptors contributes as well, apart from 
α1-adrenoceptors. The magnitude of those non-adrenergic contractions is 
comparable to adrenergic contractions, and was shown to be sufficient to 
replace α1-adrenergic tension in the human prostate in ex vivo experiments 
[23]. However, non-adrenergic receptors and the contractions mediated by 
them are beyond α1-blockers’ reach. It is assumed that the non-adrenergic 
contraction of prostate smooth muscle is the reason why the efficacy is 
limited since the treatments with α1-blockers ignore this component [22].   
 
Other current options like PDE5 inhibitors, which cover non-adrenergic 
contractions are either less efficient as α1-blockers in relaxing prostate 
smooth muscle, or as parts of combination therapy complimentary to 
α1-blockers [80]. Although combination therapies includes 2 or 3 
medications are promising to compliment each other, it should be 





and potential additive side effects [45].  
 
More importantly, apart from the current understanding of prostate smooth 
muscle contraction, the whole picture of prostate smooth muscle 
contraction may be much broader. Recently, various new concepts have 
been indicated, which may also explain why current medical therapy is not 
efficient enough [80]. 
 
1.5 Mechanisms of prostate smooth muscle contraction and 
relaxation 
 
Although the smooth muscle is equipped with different receptor subtypes 
in different organs, the mechanisms of smooth muscle 
contraction/relaxation in different body systems have a lot in common. The 
common base of regulation is that the phosphorylation level of myosin 
light chain (MLC) determines the contractile state of smooth muscle, since 
MLC phosphorylation enhances myosin-actin filament cross-bridge 
attachment and promotes cycling of actomyosin [81]. In a word, MLC 
phosphorylation results in contraction, while MLC dephosphorylation 
brings about relaxation [81]. In addition, actin polymerization and tissue 





mechnisms are regulated and induced by several intracellular signaling 
pathways. The currently well established models of the regulations are 
described in the following paragraphs.  
 
1.5.1 Contraction 
The current understanding of intracellular mechanisms mediating smooth 
muscle contraction is summarized in figure 4. Like striated muscles, 





[82, 83]. However, the extent of MLC phosphorylation 
or force of contraction does not necessarily parallel the intracellular Ca
2+
 
concentration [81]. This points to other mechanisms, and 
Ca
2+
-independent pathways of contraction regulation have also been 
recognized. Ca
2+
-dependent pathways start with agonist-induced 
activation of corresponding receptors, followed by activation of 
phospholipase C (PLC) by receptor-coupled G proteins. PLC then 
hydrolyzes phosphatidylinositol diphosphate (bound in the cell membrane) 
into diacylglycerol [84] and inositol-1,4,5-trisphosphate (IP3). IP3 triggers 
Ca
2+
 outflow from the sarcoplasmic reticulum into the cytosol, which is 
followed by depolarization of the smooth muscle cell and opening of 
voltage-gated Ca
2+
 channel [82, 83]. An influx of Ca
2+
 causes a further 
elevation of cytosolic Ca
2+





which subsequently activates MLC kinase (MLCK), resulting in MLC 
phosphorylation and force generation [81, 83, 85, 86]. In parallel, DAG 
increases the activity of protein kinase C (PKC) which inhibits MLC 
phosphatase (MLCP), resulting in inhibition of MCL dephosphorylation, 
and promotion of contraction. The receptor-coupled G protein also 
activates a Ca
2+
-independent pathway by activating guanine nucleotide 
exchange factors (GEFs). GEFs then activate the small GTPase RhoA and 
its effector Rho kinase (ROCK1/2), which can inhibit MLCP and promote 







Figure 4. Mechanisms of smooth muscle contraction. The contraction 
of smooth muscle is a result of MLC phosphorylation, which can be 
achieved by MLCK activation and MLCP inactivation, under different 





Relaxation relies on active regulations through cyclooxygenase [87], NO 
[20] or autonomic-nerve neuroendocrine pathway. Adenosine 3',5'-cyclic 





mediating smooth muscle relaxation. The cAMP is catalyzed by adenylyl 
cyclases (AC), which are activated downstream by β-adrenoceptors or 
receptors binded by COX-produced prostaglandins (PGs) [85], while 
cGMP is catalyzed by soluble guanylyl cyclase (sGC) which is activated 
by NO [20]. Cyclic AMP and cGMP activates protein kinase A [88] and 





 exchange ATPase on the sarcoplasmic reticular or 
the plasma membrane, and directly activate MLCP resulting in 















Figure 5. Regulatory mechanisms of smooth muscle relaxation. The 
relaxation of smooth muscle relies on MLC dephosphorylation, which can 
be mediated by PKA and PKG, downstream of pro-relaxation receptors or 
NO. 
  
1.6 Novel targets for inhibition of prostate smooth muscle 
contraction 
 
Considering the high prevalence among aged men, as well as the fact that 





insufficient, novel pharmacological options for medical treatment of 
LUTS suggestive of BPH are of high demand. In recent years, various 
studies have been performed to explore novel targets for potential 
treatment options for LUTS suggestive of BPH. These studies either 
identified novel targets in the classical pathways shown above, or extended 




Neurotransmitters mediate neurogenic prostate smooth muscle contraction 
through transmembrane receptors [81]. Thus, inhibition of 
neurotransmission is supposed to attenuate the contraction, what can 
potentially improve LUTS suggested of BPH. It has been shown that 
electric field stimulations (EFS)-induced contractions can be enhanced by 
a thiol-alkylating agent N-Ethylmaleimide (NEM), and are inhibited by the 
adrenergic neuron blocker guanethidine [89]. A recent study reported that 
FRAX486 and IPA3, inhibitors of P21-activated kinase (PAK) can inhibit 
contractions of prostate smooth muscle induced by EFS, but not those by 
noradrenaline and phenylephrine. Considering different PAK isoforms 
colocalized with tyrosine hydroxylase (a marker for catecholaminergic 





that PAKs might mediate prostate smooth muscle by affecting on 
adrenergic neurotransmission [90]. 
 
1.6.2 Novel membrane receptor antagonists 
G protein-coupled receptors and protein kinases and represent two 
prominent pathways for cellular signaling. Traditional receptor antagonists 
are described above and include mainly adrenergic and cholinergic ligands. 
Novel receptor antagonists either provide higher selectivity for the 
traditional targets or address new targets.  
 
AdTx1, for instance, is an α1a-adrenoceptor antagonist which may be 
highly selective for prostate or bladder neck, and it can efficiently inhibit 
adrenergic contraction of prostate smooth muscle [65, 91]. 
 
The thromboxane A2 receptor antagonist picotamide showed inhibition 
effect of TXA2- and endothelin-mediated contraction. Surprisingly, the 
α1-adrenergic and neurogenic contractions were also reported to be 
inhibited in the human prostate [78, 92]. 
 





secreted from the sympathetic synapse in the prostate after EFS [93]. 
Studies showed that P2X-receptors (ATP receptors) indeed emerge in the 
prostate smooth muscle [93]. P2X-receptor antagonists may therefore 
relieve urethral compression from the prostate [93].  
 
Epithelial cannabinoid receptor type 1 (CB1) receptors showed the 
inhibition effect of neurogenic prostate smooth muscle contraction of 
animal models [94].  
 
1.6.3 Protein kinases 
Protein kinases are crucial mediators in intracellular signaling, among 
which serine/threonine kinases and protein tyrosine kinases (PTKs) are the 
most important ones. PTKs and some serine/threonine kinases like 
mitogen-activated protein kinase (MAPKs) can mediate cell proliferation 
and differentiation, with the potential not only to reduce contraction but 
also to inhibit the growth of the prostate [95, 96].  
 
A recent study of the group of the author of this thesis suggested that an 
inhibitor for serine/threonine kinase 16 (STK16) inhibited non-adrenergic 





suggesting that STK16 may play a role in a non-adrenergic signal pathway 
in addition to current established pathways [97].  
 
Notably, apart from inhibiting prejunctional transmission shown by 
inhibition of EFS-induced contraction of prostate smooth muscle, the PAK 
inhibitors FRAX486 and IPA3 also inhibited endothelin-1 induced 
contraction [90]. This suggested that PAK, as an serine/threonine kinase 
may be involved not only in the transmission of sympathetic nerve but also 
in a non-neurogenic signal pathway. Inhibitors for LIM kinase, SR7826 
and LIMKi3, have been previously shown to inhibit EFS, adrenergic and 
non-adrenergic contractions of human prostate strips [98]. The c-Jun 
N-terminal kinase inhibitors SP600125 and BI-78D3 reduced 
agonist-induced adrenergic human prostate smooth muscle contractions, 
with no non-adrenergic contractions were tested [99]. Polo-like kinase 
(PLK) may also be engaged in the prostate smooth muscle contraction, as 
its inhibitors were able to inhibit α1-adrenergic contractions of human 
prostate tissues, but not the non-adrenergic contractions of them [100]. 
These findings indicated that different serine/threonine kinases may play 
roles in the prostate smooth muscle contraction through α1-adrenergic, 






Non-receptor PTKs are widely involved in crucial cell functions including 
proliferation and differentiation, with potentials not only to reduce 
contraction but also to inhibit growth of prostate. Src family kinases 
(SFKs), ZAP70 family, Tec family, JAK family and intranuclear PTK are 
among the non-receptor PTK. A previous study revealed that two 
inhibitors of SFKs, AZM475271 and PP2, can not only inhibit adrenergic 
and neurogenic contraction of human prostate smooth muscle but also 
proliferation of WPMY-1 cells (prostate stromal cell lines). Proliferation 
reduction could not be seen in c-Src-deficiency cells [101]. Focal adhesion 
kinase (FAK), a non-receptor PTK linking integrin to intracellular 
signaling pathways, has also been observed to play a role in contractile 
responses in the prostate, with FAK inhibitors being able to reduce 
adrenergic and neurogenic smooth muscle contractions of the human 
prostate [102].  
 
Recently, some anti-proliferation compounds designed for inhibiting 
tumor growth have also been shown to reduce prostate smooth muscle tone 
and to inhibit the growth of prostate cells at once. Thus, onvansertib, as a 
selective PLK1 inhibitor, was designed to inhibit tumor growth including 
prostate cancer. Recently, it was shown to be able to reduce neurogenic, 
adrenergic, non-adrenergic and purinergic contractions of human prostate 





mesylate (Gleevec) as a PTK inhibitor, has also been shown to facilitate 
the relaxation of human prostate strips [104].  
 
1.6.4 Small monomeric GTPase dependent pathways 
Among small GTPases, the Ras superfamily is the most important group, 
which consists of five families Rho, Ras, Rab, Arf, and Ran [105]. Rho has 
GDP/GTP-binding activity and GTPase activity, and can be activated 
when GDP–Rho is converted to GTP–Rho by GEFs, downstream of 
receptor-coupled Gα12/13. The activity of Rho kinases can then be enhanced 
by binding GTP–RhoA. Rho kinase includes ROCK1 and ROCK2, which 
inhibits MLCP and promote contraction [81, 106]. In mammals, the family 
of Rho GTPases consists of Rho (isoforms A–E, and G), Rac, Cdc42 and 
TC10. RhoA, Rac1 and Cdc42 have been the most intensively investigated 
in smooth muscle [86, 107]. The ROCK1/2 inhibitor Y27632 and the 
ROCK-2-selective inhibitor fasudil have been reported to inhibit 
adrenergic contraction of human prostate smooth muscle [108]. Y27632 
has also been found to inhibit non-adrenergic contractions of the human 
prostate smooth muscle [109]. The Rac inhibitors NSC23766 (a selective 
inhibitor of Rac1-GEF interaction) and EHT1864 (a potent inhibitor for 
Rac family) have been found to inhibit neurogenic and adrenergic 





another recent study using human prostate strips, EHT1864 also inhibits 
endothelin-1- and U46619-induced contractions, and NSC23766 inhibits 
U46619-induced contraction [22]. Apart from this, both inhibitors show 
inhibition of growth of prostate stromal cells, so that a potential to target 
both dynamic and mechanical compression of prostatic urethral in BPH 
patients with LUTS was concluded [110]. ARF6 is another small 
monomeric GTPase. Cytohesins, belonging to GEFs, may activate ARFs 
directly [41]. The Sec7 inhibitor H3 (secinH3), which is a 
cytohesin-specific inhibitor, was reported to inhibit ARF6, but not RhoA 
or Rac1. In parallel, secinH3 has been revealed to inhibit neurogenic, 
adrenergic and non-adrenergic contractions of human prostate smooth 
muscle [111]. NAV2729, an inhibitor for ARF6, has also been found to 
inhibit EFS-induced and adrenergic contractions of human prostate strips 
[41]. These findings indicate that ARF6 may also be involved in prostate 
smooth muscle contraction. 
 
Cyclic AMP and cGMP are second messengers mediating smooth muscle 
relaxation. Cyclic AMP is produced by AC, downstream of 
β-adrenoceptors or COX-produced PGs [81, 106, 112], while cGMP is 
formed by soluble guanylyl cyclase (sGC) which is activated by NO [20]. 
Cyclic AMP and cGMP activate PKA [88] and PKG respectively, as well 





Tiam1, Vav2, Rac, etc to mediate smooth muscle relaxation [111]. Direct 
stimulation of cAMP and cGMP was also reported to be able to reverse 
ET-1-induced smooth muscle contraction from the human prostate [113]. 
PDE inhibitors prevent PDEs from degrading cAMP and cGMP, thus 
promote relaxation of the prostate smooth muscle. Apart from PDE5 
inhibitors which are already approved for current therapy of LUTS 
suggestive of BPH, the PDE10-selective inhibitor TC-E 5005 has also 
been reported to inhibit mainly adrenergic, neurogenic human prostate 
smooth muscle contractions [114]. On the other hand, the cAMP effector 
EPAC may be involved in prostate relaxation, as its activators pCPT and 
OME were able to inhibit phenylephrine-induced human prostate smooth 
muscle contraction under addition of cyclooxygenase inhibitor 
indomethacin. KMUP-1, as an sGC activator and PDE5 inhibitor, has been 
observed to facilitate the accumulation of cAMP/cGMP and to upregulate 
expression of sGC, PKG, and PKA protein in rat prostate, as well as to 
inhibit the prostate smooth muscle contraction induced by phenylephrine 
[115].  
 
1.6.5 Plant extracts 
Isosamidin, an extract of Peucedanum japonicum was reported to attenuate 





Similar effects were also observed by Honokiol, a constituent of Magnolia 
species, with its ability to inhibit adrenergic contraction of human prostate 
strips, apart from which, it also facilitated apoptosis of stromal cells [117]. 
According to research using rat tissues, Serenoa repens, a liposterolic 
extract of saw palmetto has been found to significantly reduce prostate 
smooth muscle contractile responses via a non-specific mechanism [118].  
 
1.6.6 Targets of metabolic syndrome 
Metabolic syndrome comprises disorders like hypertension, 
atherosclerosis, obesity, and insulin resistance, and atherogenic 
dyslipidemia, caused by genetic and acquired factors [41, 119]. Recently, 
the relationship between LUTS and metabolic syndrome has been shown 
by clinical data. In patients with metabolic syndrome, adipokines play a 
central role for pathophysiology [41]. Ghrelin is one of such adipokines. At 
preclinical level, it has been reported that ghrelin may promote prostate 
enlargement, growth of prostate cells, and prostate smooth muscle tone 
[41]. Combination therapy with omega-3 fatty acids plus tamsulosin and 
finasteride has been used in the treatment of men with LUTS and BPH in a 






1.7 Integrins and integrin-linked kinase 
 
Integrins are transmembrane proteins widely expressed on the surface of 
various cells in different organs. Integrins are heterodimers which always 
consist of two subunits: α and β. In mammals, there are eighteen α and 
eight β subunits of integrins, and they assemble a total of 24 acknowledged 
integrins through non-covalent bonds between α and β [121, 122]. 
Integrins mediate adhesion and intercommunication between cells as well 
as between cells and extracellular matrix. Extracellular ligands for 
integrins outer domains embrace fibronectin, vitronectin, collagen, and 
laminin, while cytoplasmic domains of integrins are linked to the actin 
cytoskeleton as well as signaling molecules [121, 122]. Through these 
integrin-related signaling molecules, signals go across the membrane and 
regulate cell function, proliferation, differentiation, migration, 
morphology, mechanical homeostasis, as well as tissue regeneration and 
their integrity. Among these signaling molecules, kinases like 
integrin-linked kinase (ILK), FAK and Src family are found crucial. FAK 
and Src family have been revealed to effect on smooth muscle contraction 
of human prostate tissue [101, 102]. 
 





studies showed that the inhibition or conditional deletion of β1 integrins 
can inhibit smooth muscle in cardiovascular and respiratory systems [123, 
124]. However, the roles of integrins and ILK in smooth muscle 
contractions have never been investigated in the prostate. In current studies 
concerning smooth muscle in the lower urinary tract system, only integrin 
αv was shown to mediate contractility of human bladder smooth muscle 
cells in vitro [102]. 
 
Thus, based on integrin-functions in organs and cell types outside the 
lower urinary tract, and considering the recently suggested role of Src 
family kinases and FAKs in prostate smooth muscle [101, 102, 121], a role 
of integrins and ILK for regulation of prostate smooth muscle contraction 





2 Objective of this thesis 
 
Prostate smooth muscle contraction accounts for dynamic urethral 
obstruction in LUTS suggestive of BPH. Thus, inhibiting prostate smooth 
muscle is one of the most important strategies in the medical treatment. 
However, the current medicational therapies have their respective 
limitations.  
 
To effectively reduce prostate tone, the ideal therapy should consider not 
only adrenergic but also non-adrenergic contraction. Thus, if one 
compound can have a different or wider spectum than α1-blockers, i.e. also 
affect non-adrenergic contractions, it would be attractive. Recently, 
several compounds have been found to potently inhibit non-adrenergic 
contractions with or without affecting the adrenergic contractions of the 
prostate smooth muscle [90, 97]. Some compounds showed such effect, 
however, there is no evidence showing that the effects are confined in the 
prostate or the lower urinary tract. Non-selective effects may bring about 
side effects outside the lower urinary tract, which contribute to 
discontinuation. Thus, targets with multiple functional isoforms and 





direction for developing new medications. Integrins are assembled by 
various α and β subunits and distributed heterogeneously in different 
organs. In this study, the α2β1 inhibitor BTT3033, the α4β1/α9β1 inhibitor 
BOP, and the ILK inhibitor Cpd22 were to tested to find out possible roles 
of these targets in prostate smooth muscle contraction, which has never 
been reported. Therefore the aim of this thesis was to address the following 
questions:  
(1) Are integrins targeted by BTT3033 and BOP and ILK expressed in the 
human prostate?  
(2) Are they expressed in smooth muscle cells or in glandular cells of the 
human prostate?  
(3) Does BTT3033 inhibit neurogenic, non-adrenergic, or 
α1-adrenoceptor-induced contractions of human prostate strips?  
(4) Does BOP inhibit neurogenic, non-adrenergic, or 
α1-adrenoceptor-induced contractions of human prostate strips?  
(5) Does Cpd22 inhibit neurogenic, non-adrenergic, or 
α1-adrenoceptor-induced contractions of human prostate strips? 




3 Materials and methods 
 
3.1 Reagents and devices 
 
Table 1. Reagents used in this study. 
 
Products Manufacturer 
Potassium chloride (KCl) Roth, Germany 
 
Sodium chloride (NaCl) Roth, Germany 
 
Magnesium sulfate heptahydrate Roth, Germany 
 
(MgSO4•7H2O)  
Sodium bicarbonate (NaHCO3) Roth, Germany 
 
D(+)-Glucose Roth, Germany 
 
Milk powder Roth, Germany 
 
Calcium chloride dihydrate Sigma-Aldrich, USA 
(CaCl2•2H2O)  
Potassium hydrogen phosphate Applichem, Germany 
(KH2PO4)  
L-Norepinephrine hydrochloride Sigma-Aldrich, USA 
(R)-(−)-Phenylephrine hydrochloride Sigma-Aldrich, USA 
Methoxamine hydrochloride Sigma-Aldrich, USA 
Custodiol® HTK cardioplegia Dr. Franz Köhler Chemie, Germany 
U46619 Enzo, USA 
Endothelin-1 Enzo, USA 
Cpd22 Merck, Darmstadt, Germany 




BOP Tocris, UK 
BTT3033 Tocris, UK 
Dimethyl sulfoxide (DMSO) Roth, Germany 
Rabbit anti-integrin α2b (#13807) Cell Signaling Technology, USA 
Rabbit anti-integrin α4 (#4600) Cell Signaling Technology, USA 
Rabbit anti-integrin α9 (PA5-27771) Invitrogen, Carlsbad, CA, USA 
Mouse anti-integrin β1 (TA807138) Origene, Rockville, MD, SA 
Rabbit anti-integrin β1 (#35784) Signalway Antibody, College Park,  
 MD, USA 
Rabbit anti ILK1 (#3862)    Cell Signaling Technology, USA 
Mouse monoclonal anti- Santa Cruz Biotechnology, USA 
pan-cytokeratin (sc-8018)  
Mouse monoclonal anti- Santa Cruz Biotechnology, USA 
calponin 1/2/3 (sc-136987)  
Mouse monoclonal anti-PSA Santa Cruz Biotechnology, USA 
(sc-7316)  
Mouse monoclonal anti-β-actin Santa Cruz Biotechnology, USA 
(sc-47778)  
Biotinylated horse anti-mouse IgG Vector Laboratories, CA, USA 
Biotinylated goat anti-rabbit IgG Vector Laboratories, CA, USA 
Chemiluminescence ECL Hyperfilm GE Healthcare, Germany 
Cy3-conjugated goat anti-mouse IgG Millipore, USA 
4’,6’-diamidino-2-phenylindole- Invitrogen, Camarillo, CA, USA 
dihydrochloride (DAPI)  
Bovine serum albumin Gibco, USA 
Cy5-conjugated goat anti-rabbit IgG Millipore, USA 
10X Reaction Buffer Thermo Fisher Scientific, USA 
Film developers Kodak, USA 
 
 




Table 2: Devices used in this study.    
                                         
Devices Manufacturer 
Tissue Bath System-720MO Danish Myotechnology, Denmark 
Tissue Bath System-720M Danish Myotechnology, Denmark 
Electrical Stimulator-CS4 Danish Myotechnology, Denmark 
Water bath Memmert, Bayern, Germany 
Lab pump KNF- Neuberger, USA 
Vibration shaker-Vortex 3 IKA, Staufen, Germany 
Protran® nitrocellulose membranes Schleicher & Schuell, Germany 
Gel electrophoresis system Bio-rad, Germany 
Superfrost® microscope slides Thermo Fisher, USA 
Laser scanning microscope Leica SP2, Germany 
 
3.2 Human prostate tissues 
 
Human prostate tissue from a total of n=173 patients were obtained from 
radical prostatectomy for prostate cancer performed at the Department of 
Urology, Klinikum Großhadern, Ludwig-Maximilians University. Tissues 
from patients who previously had transurethral resection of the prostate 
(TURP) or brachytherapy were excluded. The tissues were transported to 
the Department of Pathology from the operation room immediately after 
the protates were removed from the patients, within Custodiol® 
cardioplegia organ-protection fluid with HTK 




(histidine-tryptophan-ketoglutarate). Prostate samples were prepared by 
the pathologists within 30 minutes after the prostate was detached from 
each patient. The prostate was cut along the front middle line 
longitudinally until the urethra, and a sample was cut from the periurethral 
zone through the section surface, where smooth muscle is abundant and the 
risk of tumor is low. Tissues were tumor-free and showed no 
macroscopical signs of inflammation, as checked by experienced 
pathologists.  
 
The tissues were transported to the laboratory in Custodiol® fluid, and cut 
into 4 smaller strips before being spiked on the needles in the organ bath. 
The exceptions were the prostate tissue designed to be used in Western 
blotting or immunofluorescence experiments, which were transferred to 
-80 °C after being shock frozen in liquid nitrogen. The whole process took 
less than 90 minutes after the removal of the prostate from the patient to the 
start of the organ experiment or the accomplishment of storage at -80 °C.  
 
3.3 Western blotting 
 
 Under Custodiol, prostate tissue samples of about 0.3 x 0.1 x 0.1 




cm were cut from prostate tissues. After siphoning off residual 
Custodiol, the pieces were shock-frozen with liquid nitrogen and 
moved to -80°C for storage.  
 Frozen prostate tissues were homogenized in a buffer containing 25 
mM Tris/HCl, 10 µM phenylmethanesulfonyl fluoride, 1 mM 
benzamidine, and 10 µg/ml leupeptin hemisulfate, using the 
FastPrep®-24 system with matrix A (MP Biomedicals, Illkirch, 
France).  
 The homogenates were centrifuged at 20,00g for 4 min, and the 
supernatants were collected. 
 Aliquots of supernatants were assayed for protein concentration 
using the Dc-Assay kit (Biorad, Munich, Germany)  
 In parallel, remaining the supernatant was boiled for 10 min with 
sodium dodecyl sulfate (SDS) sample buffer (Roth, Karlsruhe, 
Germany).  
 Samples (20 μg/lane) were subjected to SDS-polyacrylamide gel 
electrophoresis. 
 The proteins were electroblotted on Protran® nitrocellulose 
membranes (Schleicher & Schuell, Dassel, Germany). 
 Membranes were blocked with phosphate-buffered saline (PBS) 
containing 5 % milk powder (Roth, Karlsruhe, Germany) 





 The membranes were then incubated with rabbit anti-integrin α2b 
(#13807) (Cell Signaling Technology, Danvers, MA, USA), 
rabbit anti-integrin α4 (#4600) (Cell Signaling Technology), 
rabbit anti-integrin α9 (PA5-27771) (Invitrogen, Carlsbad, CA 
USA), mouse anti integrin β1 (TA807138) (Origene, Rockville, 
MD, USA), rabbit anti ILK1 (#3862) (Cell Signaling Technology), 
mouse monoclonal anti-pan-cytokeratin (sc-8018), mouse 
monoclonal anti calponin 1/2/3 (sc-136987), mouse monoclonal 
anti-PSA (sc-7316), or mouse monoclonal anti-β-actin antibody 
(sc-47778) (if not other stated, from Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) at 4 °C overnight. All primary antibodies 
were diluted in PBS containing 0.1 % Tween 20 (PBS-T) and 5 % 
milk powder. 
 The membranes were then washed with PBS-T three times, with five 
minutes each time. 
 Then, the membranes were incubated with secondary biotinylated 
horse anti-mouse or horse anti-rabbit IgG (Vector Laboratories, 
Burlingame, CA, USA), followed by incubation with avidin and 
biotinylated horseradish peroxidase (HRP) from the “Vectastain 
ABC kit” (Vector Laboratories, Burlingame, CA, USA) both 
diluted 1:200 in PBS. Incubation took 1 h at room temperature. 




 Membranes were washed three times every five minutes with 
PBS-T after incubation with secondary antibodies or biotin-HRP.  
 Membranes were washed with PBS once. 
 Blots were developed with enhanced chemiluminescence (ECL) 
using ECL Hyperfilm (GE Healthcare, Freiburg, Germany).  
 
3.4 Fluorescence staining 
 
 Human prostate tissues were embedded in optimal cutting 
temperature (OCT) compound, then snap-frozen in liquid 
nitrogen and transfered to -80 °C for storage. 
 Sections (8 µm) were cut in a cryostat and collected on 
Superfrost® microscope slides. The slides were washed with 
PBS. 
 Sections were post-fixed in methanol at -20 °C and blocked in 1 % 
bovine serum albumin for 30 min. 
 Sections were then incubated with primary antibody overnight, at 
room temperature all the time during the incubation.  
 For double labeling, the following primary antibodies were used: 
rabbit anti-integrin α2b (#13807) (Cell Signaling Technology, 




Danvers, MA, USA), rabbit anti-integrin α4 (#4600) (Cell 
Signaling Technology), rabbit anti-integrin α9 (PA5-27771) 
(Invitrogen, Carlsbad, CA USA), rabbit anti-integrin β1 (#35784) 
(Signalway Antibody, College Park, MD, USA), rabbit anti-ILK1 
(#3862) (Cell Signaling Technology), mouse monoclonal 
anti-pan-cytokeratin (sc-8018) (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), or mouse monoclonal anti-calponin 1/2/3 
(sc-136987) (Santa Cruz Biotechnology, Santa Cruz). 
 Control groups were stained without any primary antibody. 
 The sections were then washed with PBS-T three times, with five 
minutes each time. 
 Binding sites were visualized using biotinylated Cy3-conjugated 
goat anti-mouse IgG (AP124C) (Millipore, Billerica, MA, US) 
and Cy5-conjugated goat anti-rabbit IgG (Millipore, Billerica, 
MA, US).  
 The sections were then washed with PBS-T three times, with two 
minutes each time. 
 Nuclei were counterstained with 
4’,6’-diamidino-2-phenylindole-dihydrochloride (DAPI) 
(Invitrogen, Camarillo, CA, USA). 
 The sections were then rinsed in PBS-T three times with two minutes 





 The sections were dehydrated with 95% ethanol for two min, and 
then 100% ethanol twice with three minutes each time. 
 Anti-fade mounting medium was applied. 
 Immunolabeled sections were analyzed using a laser scanning 
microscope (Leica SP2, Wetzlar, Germany). Fluorescence was 
recorded with separate detectors.  
 
3.5 Prostate tissue contraction measurements 
 
 Preparation of Krebs–Henseleit (KH) solution and its two sub 
solutions: the compositions of sub solutions KH1 and KH2 are 
described in table 4 below. As table 4 shows, 43.5 ml of KH1 and 
1.62 g glucose were added in 1000ml double distilled (D-D) water. 
Carbogen (95 % O2, 5% CO2) was continuously introduced into the 
solution for at least 20 min, before 43.5 ml of KH2 was added. The 
KH solution was always kept at 37 °C and under continuous 
carbogen (95% O2 and 5% CO2) inflow (as shown in figure 6). 





Figure 6. The KH solution in a water bath and under carbogen inflow. 
The KH solution was kept in 37 °C thermostatic water bath and inserted 










Table 3: Composition of solutions used in organ baths. 
 
Solution Component  
Krebs-Henseleit solution  KH1 43.5ml 
in organ bath (Guirgis et al.) Glucose 1.62g 
 KH2 43.5ml 
 Distilled water 1000ml 
   
Presolution 1 (KH1) NaCl 172.4g 
 KCl 8.8g 
 CaCl2•2H2O 9.2g 
 KH2PO4 4.1g 
 MgSO4•7H2O 7.4g 
 Distilled water add to 1000ml 
   
Presolution 2 (KH2)  NaHCO3 32.5g 
 Distilled water add to 1000ml 
 
 
 Pretension: Each chamber was filled with 10 ml KH solution after 
washing three times with KH solution. The organ bath chambers 
were under continuous carbogen inflow and a stabilized temperature 
of 37 °C, which was maintained by the setting of the myograph 
system. Strips of prostate tissue were cut into 4 pieces of 
approximately 0.6 × 0.3 × 0.3 cm as homogenically as possible, 
which were then spiked on the paired needles in the chambers by a 
needle distance of 0.4 cm (as shown in figure 7). The tensions of the 




prostate tissues were adjusted with the aim that the tensions were 
stable at 4.9mN. In the pretension process, usually, at least three 
stretches maximal to 6.0 mN (the intervals were 15 min) were 
required for rebalancing, considering the tissue tends to relax before 
having stabilized during equilibration at 4.9 +/- 0.1 mN in 
minimally 45 min. 
 
 
Figure 7. The myograph machine and strips in the organ bath 
chambers. A myograph device contains 4 chambers. Each chamber has a 
capacity of 10 ml liquid, with a independent adjustment knob and a force 
transducer. 
 
 Reference contraction of prostate strips: KCl-induced contraction of 
prostate strips was induced by addition of 400 µL of 2 M KCl 
solution to reach a final KCl concentration of 80 mM. After the 
contraction reached the peak, the chamber was washed by KH 
solution 3 times. 




 Incubation: BTT3033, Cpd22 and BOP were dissolved in DMSO, 
and 10 µl of BTT3033 (1 mM), Cpd22 (3 mM) or BOP (1 mM) were 
added to chambers, which were regarded as experiment group, with 
the final concentrations of 1 μM for BTT3033, 3 μM for Cpd22 and 
1 μM for BOP. Correspondingly, 10 µl of DMSO was added in 
chambers which were regarded as controls. Incubation of inhibitors 
or solvent took 30 min before the contraction induction by EFS or 
agonists was started. 
 EFS application or agonist addition: EFS was applied in doubling 
increasing frequences from 2Hz to 32Hz. Addition of agonists was 
conducted as shown in table 5 to achieve cumulative concentrations 
of 0.1 µM, 0.3 µM, 1 µM, 3µM, 10 µM (not used in ET-1), 30 µM 
(not used in ET-1) and 100µM (not used in U46619 and ET-1).  
 Temperature setting and force calibration: The temperature  setting 
of myograph system and the flask water bath were adjusted to keep 
the KH solution in the chambers or flask 37 °C according to the 
accessory probe or kerosene thermometer.  
 Calibration of the force transducer was performed with an 1:1  
L-shaped right-angle lever, until the force output showed 9.81+/-0.1 
mN after a two-gram standard weight was placed on the vertical part 
of the lever. Temperature settings and force calibrations were done 
every three months or every time after relocation of the machine or a 




replacement of force transducer. 
 
3.6 Data analysis and statistics 
 
Data collected from the contraction experiments are presented as means 
± standard deviation (SD) [127]. One-way analysis of variance [128] 
[128] was used to compare the whole response curves, and 
multi-variance analysis was used to compare contractions at each 
concentrations. P values <0.05 were considered significant. This study 
and analyses were designed to be exploratory, so p values are 
considered as descriptive. Groups (control and inhibitor group) have 
identical group size if being compared. No data or experiments were 








4.1 Detection of integrins, ILK, PSA, calponin and 
cytokeratin in human prostate tissues by Western blotting 
 
Seven human prostate tissues were subjected to Western blotting for 
detection of integrin subunits α2b, α9, α4, β1, as well as ILK1, PSA, 
calponin, pan-cytokeratin, and β-actin using corresponding antibodies. 
PSA can serve as an indicator for the BPH degree, calponin as a maker for 
smooth muscle content and pan-cytokeratin as a maker for glandular 
epithelial cells [97]. Beta-actin is a housekeeping protein used as a loading 
control. Detection of all antigens revealed bands with sizes matching the 
expected molecular weight of the corresponding proteins. These presumed 
bands for all related integrin subunit and ILK1 occurred using all included 
prostate tissues, whereas the intensity of these bands varied between 
different tissues, and the pattern of intensity variation differed between 
different antigens (figure 8). Similarly, Western blot analysis demonstrated 
varying content of PSA in samples of different patients, reflecting 
divergent degree of BPH in different prostates. Detection of calponin 





included in Western blot analysis, while cytokeratins reflected the 








Figure 8: Detection of integrin subunits and ILK in human prostate 
tissues. Western blot analysis was performed using antibodies for proteins 
of interest and β-actin serving as housekeeping protein and loading control. 
The names and sizes of each target protein are noted on the right and 
positions of marker bands are noted on the right. Shown are blots with all 






4.2 Detection of the expression and the location of integrins 
(subunits) of interest and ILK by fluorescence staining 
 
Double stainings of prostate sections were performed using antibodies for 
integrin α2, α4, α9, β1 and ILK1, respectively, together with an anti-calponin 
antibody as a marker of smooth muscle cells, or an anti-pan-cytokeratin 
antibody as a marker of glandular epithelial cells. Typical prostate 
histological structures were observed, as the stromal areas showed 
immunoreactivity to the antibody for calponin, and the surrounding glands 
showed immunoreactivity to the antibody for pan-cytokeratin in the 
glandular epithelia. Immunoreactivity for α2, α9, β1 integrin emerged in 
both the stroma and the glands, where it colocalized with both calponin and 
pan-cytokeratins (Figure 10, 11, 13), suggesting that integrin subunit α2, α9, 
β1 are located in smooth muscle, and also in glandular epithelium. 
Immunoreactivity for ILK1 colocalized with calponin but not 
pan-cytokeratin (Figure 9), suggesting that ILK1 integrin located in 
smooth muscle but not in the glandular epithelium. Integrin subunit α4 
emerged in both the stroma and the glandular, but was colocalized with 






      
 
Figure 9: Immunofluorescence staining of human prostate tissues for 
ILK1. Sections were double-stained with antibodies for ILK1 (indicated 
as red), in combination with antibodies for calponin (a marker for smooth 
muscle cells) or pan-cytokeratin (a marker for glandular epithelial cells), 
both indicated as green. Yellow color in fusion pictures suggests the 
colocalization of targets. Presented are representative immunofluorescence 
staining sets from series with tissues from n=5 patients. Negative controls 
were performed only without primary antibodies (lower panel, right image 







      
 
Figure 10: Immunofluorescence staining of human prostate tissues for 
integrin α2. Sections were double-stained with antibodies for integrin α2 
(indicated as red), in combination with antibodies for calponin (a marker 
for smooth muscle cells) or pan-cytokeratin (a marker for glandular 
epithelial cells), both indicated as green. Yellow color in fusion pictures 
suggests the colocalization of targets. Presented are representative 
immunofluorescence staining sets from series with tissues from n=5 
patients. Negative controls were performed only without primary 








      
 
Figure 11: Immunofluorescence staining of human prostate tissues for 
integrin β1. Sections were double-stained with antibodies for integrin β1 
(indicated as red), in combination with antibodies for calponin (a marker 
for smooth muscle cells) or pan-cytokeratin (a marker for glandular 
epithelial cells), both indicated as green. Yellow color in fusion pictures 
suggests the colocalization of targets. Presented are representative 
immunofluorescence staining sets from series with tissues from n=5 
patients. Negative controls were performed only without primary 








      
 
Figure 12: Immunofluorescence staining of human prostate tissues for 
integrin α4. Sections were double-stained with antibodies for integrin α4 
(indicated as red), in combination with antibodies for calponin (a marker 
for smooth muscle cells) or pan-cytokeratin (a marker for glandular 
epithelial cells), both indicated as green. Yellow color in fusion pictures 
suggests the colocalization of targets. Presented are representative 
immunofluorescence staining sets from series with tissues from n=5 
patients. Negative controls were performed only without primary 








      
 
Figure 13 Immunofluorescence staining of human prostate tissues for 
integrin α9. Sections were double-stained with antibodies for integrin α9  
(indicated as red), in combination with antibodies for calponin (a marker 
for smooth muscle cells) or pan-cytokeratin (a marker for glandular 
epithelial cells), both indicated as green. Yellow color in fusion pictures 
suggests the colocalization of targets. Presented are representative 
immunofluorescence staining sets from series with tissues from n=5 
patients. Negative controls were performed only without primary 
antibodies (lower panel, right image in each image group). 
 







4.3.1 Effect of BTT3033 on EFS-induced contractions.  
EFS (2-32 HZ, 5 frequences proportionally increased) induced 
contractions in a frequency-dependent way, which were inhibited by 
BTT3033 (1 μM). Analysis of variance showed significant inhibition by 
BTT3033 in a whole comparison of two groups (p<0.01), and 
multivariance analysis showed significant inhibition at EFS frequences of 












































Figure 14. Contractions of human prostate strips measured in the organ 
bath, which were induced by EFS in proportionally growing frequence. 
The effects of BTT3033 on EFS-induced contractions were compared with 
solvent (control) in n=5 independent experiments with tissues from 5 
patients. Tissue from each patient was allocated to 4 samples, from which 
2 were allocated to the control group, and the 2 others to the inhibitor group. 
Tissues were incubated with inhibitors (inhibitor group) or solvent (control 
group) after KCl-induced contractions were measured. Tensions were 
calculated as % of 80 mM KCl-induced contractions to eliminate the effect 
of heterogeneities on tissue contractions. Data are presented as means ± SD 







4.3.2 Effect of BTT3033 on U46619-induced contractions.  
U46619 (0.1 to 30 μM, 6 cumulative concentrations) induced contractions 
in a concentration-dependent way, which were inhibited by BTT3033 (1 
μM). Analysis of variance showed significant inhibition by BTT3033 in 
comparison of whole concentration-response curves (p<0.03), while 
multivariance analysis showed no significant difference at each 
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Figure 15. Contractions of human prostate strips measured in the organ 
bath, which were induced by U46619 in cumulative concentrations. The 
effects of BTT3033 on U46619-induced contractions were compared with 
solvent (control) in n=5 independent experiments with tissues from 5 
patients. Tissue from each patients was allocated to 4 samples, from which 
2 were allocated to the control group, and the 2 others to the inhibitor group. 
Tissues were incubated with inhibitors (inhibitor group) or solvent (control 
group) after KCl-induced contractions were measured. Tensions were 
calculated as % of 80 mM KCl-induced contractions to eliminate the effect 
of heterogeneities on tissue contractions. Data are presented as means ± SD 






4.3.3 Effect of BTT3033 on Endothelin-1-induced contractions. 
Endothelin-1 (0.1 to 3 μM, 4 cumulative concentrations) induced 
contractions in a concentration-dependent way, which were not inhibited 
by BTT3033 (1 μM). Analysis of variance showed no significant inhibition 
by BTT3033 in comparison of whole concentration-response curves, and 
multivariance analysis showed no significant inhibition at each 
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Figure 16. Contractions of human prostate strips measured in the organ 
bath, which were induced by endothelin-1 in cumulative concentrations. 
The effects of BTT3033 on endothelin-1-induced contractions were 
compared with solvent (control) in n=6 independent experiments with 
tissues from 6 patients. Tissue from each patient was allocated to 4 samples, 
from which 2 were allocated to the control group, and the 2 others to the 
inhibitor group. Tissues were incubated with inhibitors (inhibitor group) or 
solvent (control group) after KCl-induced contractions were measured. 
Tensions were calculated as % of 80 mM KCl-induced contractions to 
eliminate the effect of heterogeneities on tissue contractions. Data are 






4.3.4 Effect of BTT3033 on noradrenaline-induced contractions. 
Noradrenaline (0.1 to 100 μM, 7 cumulative concentrations) induced 
contractions in a concentration-dependent way, which were inhibited by 
BTT3033 (1 μM). Analysis of variance showed significant inhibition by 
BTT3033 in comparison of whole concentration-response curves (p<0.01), 
and multi-variance analysis showed significant inhibition at noradrenaline 








































Figure 17. Contractions of human prostate strips measured in the organ 
bath, which were induced by noradrenaline in cumulative concentrations. 
The effects of BTT3033 on noradrenaline-induced contractions were 
compared with solvent (control) in n=5 independent experiments with 
tissues from 5 patients. Tissue from each patient was allocated to 4 samples, 
from which 2 were allocated to the control group, and the 2 others to the 
inhibitor group. Tissues were incubated with inhibitors (inhibitor group) or 
solvent (control group) after KCl-induced contractions were measured. 
Tensions were calculated as % of 80 mM KCl-induced contractions to 
eliminate the effect of heterogeneities on tissue contractions. Data are 
presented as means ± SD on each concentration of noradrenaline (*P<0.05 






4.3.5 Effect of BTT3033 on phenylephrine-induced contractions.  
Phenylephrine (0.1 to 100 μM, 7 cumulative concentrations) induced 
contractions in a concentration-dependent way, which were not inhibited 
by BTT3033 (1 μM). Analysis of variance showed no significant inhibition 
by BTT3033 in comparison of whole concentration-response curves, and 
multivariance analysis showed no significant inhibition at each 




































Figure 18. Contractions of human prostate strips measured in the organ 
bath, which were induced by phenylephrine in cumulative concentrations. 
The effects of BTT3033 on phenylephrine-induced contractions were 
compared with solvent (control) in n=6 independent experiments with 
tissues from 6 patients. Tissue from each patient was allocated to 4 samples, 
from which 2 were allocated to the control group, and the 2 others to the 
inhibitor group. Tissues were incubated with inhibitors (inhibitor group) or 
solvent (control group) after KCl-induced contractions were measured. 
Tensions were calculated as % of 80 mM KCl-induced contractions to 
eliminate the effect of heterogeneities on tissue contractions. Data are 
presented as means ± SD on each concentration of phenylephrine. 
 
4.3.6 Effect of BTT3033 on methoxamine-induced contractions.  
Methoxamine (0.1 to 100 μM, 7 cumulative concentrations) induced 
contractions in a concentration-dependent way, which were inhibited by 
BTT3033 (1 μM). Analysis of variance showed significant inhibition by 
BTT3033 in comparison of whole concentration-response curves (p<0.03), 
while multivariance analysis showed no significant difference at each 
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Figure 19. Contractions of human prostate strips measured in the organ 
bath, which were induced by methoxamine in cumulative concentrations. 
The effects of BTT3033 on methoxamine-induced contractions were 
compared with solvent (control) in n=6 independent experiments with 
tissues from 6 patients. Tissue from each patient was allocated to 4 samples, 
from which 2 were allocated to the control group, and the 2 others to the 





solvent (control group) after KCl-induced contractions were measured. 
Tensions were calculated as % of 80 mM KCl-induced contractions to 
eliminate the effect of heterogeneities on tissue contractions. Data are 
presented as means ± SD on each concentration of methoxamine. 
 
 
4.4 Effect of BOP on prostate smooth muscle contractions.  
 
4.4.1 Effect of BOP on EFS-induced contractions. 
EFS (2-32 HZ, 5 frequences proportionally increased) induced 
contractions in a frequency-dependent way, which were not inhibited by 
BOP (1 μM). Analysis of variance showed no significant inhibition by 
BOP in comparison of whole concentration-response curves, and 
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Figure 20. Contractions of human prostate strips measured in the organ 
bath, which were induced by EFS in proportionally growing frequence. 
The effects of BOP on EFS-induced contractions were compared with 
solvent (control) in n=5 independent experiments with tissues from 5 
patients. Tissue from each patient was allocated to 4 samples, from which 
2 were allocated to the control group, and the 2 others to the inhibitor group. 
Tissues were incubated with inhibitors (inhibitor group) or solvent (control 
group) after KCl-induced contractions were measured. Tensions were 
calculated as % of 80 mM KCl-induced contractions to eliminate the effect 
of heterogeneities on tissue contractions. Data are presented as means ± SD 






4.4.2 Effect of BOP on U46619-induced contractions.  
U46619 (0.1 to 30 μM, 6 cumulative concentrations) induced contractions 
in a concentration-dependent way, which were not inhibited by BOP (1 
μM). Analysis of variance showed no significant inhibition by BOP in 
comparison of whole concentration-response curves, and multivariance 
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Figure 21. Contractions of human prostate strips measured in the organ 
bath, which were induced by U46619 in cumulative concentrations. The 
effects of BOP on U46619-induced contractions were compared with 
solvent (control) in n=6 independent experiments with tissues from 6 
patients. Tissue from each patient was allocated to 4 samples, from which 
2 were allocated to the control group, and the 2 others to the inhibitor group. 
Tissues were incubated with inhibitors (inhibitor group) or solvent (control 
group) after KCl-induced contractions were measured. Tensions were 
calculated as % of 80 mM KCl-induced contractions to eliminate the effect 
of heterogeneities on tissue contractions. Data are presented as means ± SD 






4.4.3 Effect of BOP on Endothelin-1-induced contractions.  
Endothelin-1 (0.1 to 3 μM, 4 cumulative concentrations) induced 
contractions in a concentration-dependent way, which were not inhibited 
by BOP (1 μM). Analysis of variance showed no significant inhibition by 
BOP in comparison of whole concentration-response curves, and 
multivariance analysis showed no significant inhibition at each 
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Figure 22. Contractions of human prostate strips measured in the organ 
bath, which were induced by endothelin-1 in cumulative concentrations. 
The effects of BOP on endothelin-1-induced contractions were compared 
with solvent (control) in n=5 independent experiments with tissues from 5 
patients. Tissue from each patient was allocated to 4 samples, from which 
2 were allocated to the control group, and the 2 others to the inhibitor group. 
Tissues were incubated with inhibitors (inhibitor group) or solvent (control 
group) after KCl-induced contractions were measured. Tensions were 
calculated as % of 80 mM KCl-induced contractions to eliminate the effect 
of heterogeneities on tissue contractions. Data are presented as means ± SD 






4.4.4 Effect of BOP on Noradrenaline-induced contractions.  
Noradrenaline (0.1 to 100 μM, 7 cumulative concentrations) induced 
contractions in a concentration-dependent way, which were not inhibited 
by BOP (1 μM). Analysis of variance showed no significant inhibition by 
BOP in comparison of whole concentration-response curves, and 
multivariance analysis showed no significant inhibition at each 






































B O PD M S O
 
Figure 23. Contractions of human prostate strips measured in the organ 
bath, which were induced by noradrenaline in cumulative concentrations. 
The effects of BOP on noradrenaline-induced contractions were compared 
with solvent (control) in n=6 independent experiments with tissues from 6 
patients. Tissue from each patient was allocated to 4 samples, from which 
2 were allocated to the control group, and the 2 others to the inhibitor group. 
Tissues were incubated with inhibitors (inhibitor group) or solvent (control 
group) after KCl-induced contractions were measured. Tensions were 
calculated as % of 80 mM KCl-induced contractions to eliminate the effect 
of heterogeneities on tissue contractions. Data are presented as means ± SD 





4.4.5 Effect of BOP on phenylephrine-induced contractions.  
Phenylephrine (0.1 to 100 μM, 7 cumulative concentrations) induced 
contractions in a concentration-dependent way, which were not inhibited 
by BOP (1 μM). Analysis of variance showed no significant inhibition by 
BOP in comparison of whole concentration-response curves, and 
multivariance analysis showed no significant inhibition at each 
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Figure 24. Contractions of human prostate strips measured in the organ 
bath, which were induced by phenylephrine in cumulative 
concentrations. The effects of BOP on phenylephrine-induced 
contractions were compared with solvent (control) in n=6 independent 
experiments with tissues from 6 patients. Tissue from each patient was 
allocated to 4 samples, from which 2 were allocated to the control group, 
and the 2 others to the inhibitor group. Tissues were incubated with 
inhibitors (inhibitor group) or solvent (control group) after 
KCl-induced contractions were measured. Tensions were calculated as % 
of 80 mM KCl-induced contractions to eliminate the effect of 
heterogeneities on tissue contractions. Data are presented as means ± 






4.4.6 Effect of BOP on methoxamine-induced contractions.  
Methoxamine (0.1 to 100 μM, 7 cumulative concentrations) induced 
contractions in a concentration-dependent way, which were not inhibited 
by BOP (1 μM). Analysis of variance showed no significant inhibition by 
BOP in comparison of whole concentration-response curves, and 
multivariance analysis showed no significant inhibition at each 
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Figure 25. Contractions of human prostate strips measured in the organ 
bath, which were induced by methoxamine in cumulative concentrations. 
The effects of BOP on methoxamine-induced contractions were compared 
with solvent (control) in n=6 independent experiments with tissues from 6 
patients. Tissue from each patient was allocated to 4 samples, from which 
2 were allocated to the control group, and the 2 others to the inhibitor group. 
Tissues were incubated with inhibitors (inhibitor group) or solvent (control 
group) after KCl-induced contractions were measured. Tensions were 
calculated as % of 80 mM KCl-induced contractions to eliminate the effect 
of heterogeneities on tissue contractions. Data are presented as means ± SD 






4.5 Effect of Cpd22 on prostate smooth muscle contractions.  
 
4.5.1 Effect of Cpd22 on EFS-induced contractions. 
EFS (2-32 HZ, 5 frequences proportionally increased) induced 
contractions in a frequency-dependent way, which were inhibited by 
Cpd22 (3 μM). Analysis of variance showed significant inhibition by 
Cpd22 in a whole comparison of two groups (p<0.02), and multivariance 
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Figure 26. Contractions of human prostate strips measured in the organ 
bath, which were induced by EFS in proportionally growing frequence. 
The effects of Cpd22 on EFS-induced contractions were compared with 
solvent (control) in n=5 independent experiments with tissues from 5 
patients. Tissue from each patient was allocated to 4 samples, from which 
2 were allocated to the control group, and the 2 others to the inhibitor group. 
Tissues were incubated with inhibitors (inhibitor group) or solvent (control 
group) after KCl-induced contractions were measured. Tensions were 
calculated as % of 80 mM KCl-induced contractions to eliminate the effect 
of heterogeneities on tissue contractions. Data are presented as means ± SD 
on each frequency of EFS (*P<0.05 for control vs. inhibitor of the 






4.5.2 Effect of Cpd22 on U46619-induced contractions.  
U46619 (0.1 to 30 μM, 6 cumulative concentrations) induced contractions 
in a concentration-dependent way, which were inhibited by Cpd22 (3 μM). 
Analysis of variance showed significant inhibition by Cpd22 in 
comparison of whole concentration-response curves (p<0.01), and 
multivariance analysis showed significant inhibition at U46619 








































Figure 27. Contractions of human prostate strips measured in the organ 
bath, which were induced by U46619 in cumulative concentrations. The 
effects of Cpd22 on U46619-induced contractions were compared with 
solvent (control) in n=5 independent experiments with tissues from 5 
patients. Tissue from each patient was allocated to 4 samples, from which 
2 were allocated to the control group, and the 2 others to the inhibitor group. 
Tissues were incubated with inhibitors (inhibitor group) or solvent (control 
group) after KCl-induced contractions were measured. Tensions were 
calculated as % of 80 mM KCl-induced contractions to eliminate the effect 
of heterogeneities on tissue contractions. Data are presented as means ± SD 
on each concentration of U46619 (*P<0.05 for control vs. inhibitor of the 






4.5.3 Effect of Cpd22 on Endothelin-1-induced contractions.  
Endothelin-1 (0.1 to 3 μM, 4 cumulative concentrations) induced 
contractions in a concentration-dependent way, which were not inhibited 
by Cpd22 (3 μM). Analysis of variance showed no significant inhibition by 
Cpd22 in comparison of whole concentration-response curves, and 
multivariance analysis showed no significant inhibition at each 
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Figure 28. Contractions of human prostate strips measured in the organ 
bath, which were induced by endothelin-1 in cumulative concentrations. 
The effects of Cpd22 on endothelin-1-induced contractions were compared 
with solvent (control) in n=8 independent experiments with tissues from 8 
patients. Tissue from each patient was allocated to 4 samples, from which 
2 were allocated to the control group, and the 2 others to the inhibitor group. 
Tissues were incubated with inhibitors (inhibitor group) or solvent (control 
group) after KCl-induced contractions were measured. Tensions were 
calculated as % of 80 mM KCl-induced contractions to eliminate the effect 
of heterogeneities on tissue contractions. Data are presented as means ± SD 






4.5.4 Effect of Cpd22 on Noradrenaline-induced contractions.  
Noradrenaline (0.1 to 100 μM, 7 cumulative concentrations) induced 
contractions in a concentration-dependent way, which were inhibited by 
Cpd22 (3 μM). Analysis of variance showed significant inhibition by 
Cpd22 in comparison of whole concentration-response curves (p<0.01), 
and multivariance analysis showed significant inhibition at noradrenaline 








































Figure 29. Contractions of human prostate strips measured in the organ 
bath, which were induced by noradrenaline in cumulative concentrations. 
The effects of Cpd22 on noradrenaline-induced contractions were 
compared with solvent (control) in n=6 independent experiments with 
tissues from 6 patients. Tissue from each patient was allocated to 4 samples, 
from which 2 were allocated to the control group, and the 2 others to the 
inhibitor group. Tissues were incubated with inhibitors (inhibitor group) or 
solvent (control group) after KCl-induced contractions were measured. 
Tensions were calculated as % of 80 mM KCl-induced contractions to 
eliminate the effect of heterogeneities on tissue contractions. Data are 
presented as means ± SD on each concentration of noradrenaline (*P<0.05 






4.5.5 Effect of Cpd22 on phenylephrine-induced contractions.  
Phenylephrine (0.1 to 100 μM, 7 cumulative concentrations) induced 
contractions in a concentration-dependent way, which were not inhibited 
by Cpd22 (3 μM) phenylephrine. Analysis of variance showed no 
significant inhibition by Cpd22 in comparison of whole 
concentration-response curves, and multivariance analysis showed no 
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Figure 30. Contractions of human prostate strips measured in the organ 
bath, which were induced by phenylephrine in cumulative concentrations. 
The effects of Cpd22 on phenylephrine-induced contractions were 
compared with solvent (control) in n=6 independent experiments with 
tissues from 6 patients. Tissue from each patient was allocated to 4 samples, 
from which 2 were allocated to the control group, and the 2 others to the 
inhibitor group. Tissues were incubated with inhibitors (inhibitor group) or 
solvent (control group) after KCl-induced contractions were measured. 
Tensions were calculated as % of 80 mM KCl-induced contractions to 
eliminate the effect of heterogeneities on tissue contractions. Data are 






4.5.6 Effect of Cpd22 on methoxamine-induced contractions.  
Methoxamine (0.1 to 100 μM, 7 cumulative concentrations) induced 
contractions in a concentration-dependent way, which were inhibited by 
Cpd22 (3 μM). Analysis of variance showed significant inhibition by 
Cpd22 in comparison of whole concentration-response curves (p<0.02), 
and multivariance analysis showed significant inhibition at methoxamine 
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Figure 31. Contractions of human prostate strips measured in the organ 
bath, which were induced by methoxamine in cumulative concentrations. 
The effects of Cpd22 on methoxamine-induced contractions were 
compared with solvent (control) in n=5 independent experiments with 
tissues from 5 patients. Tissue from each patient was allocated to 4 samples, 
from which 2 were allocated to the control group, and the 2 others to the 
inhibitor group. Tissues were incubated with inhibitors (inhibitor group) or 
solvent (control group) after KCl-induced contractions were measured. 
Tensions were calculated as % of 80 mM KCl-induced contractions to 
eliminate the effect of heterogeneities on tissue contractions. Data are 
presented as means ± SD on each concentration of methoxamine (*P<0.05 







In this thesis, it is demonstrated that the integrin α2β1 inhibitor BTT3033 (1 
μM) and the ILK inhibitor Cpd22 (3 μM) can inhibit neurogenic and 
thromboxane A2-induced human prostate smooth muscle contraction ex 
vivo. Very slight inhibitions were observed on noradrenaline- and 
methoxamine-induced contractions as well, which may be probably 
neglectable, as the inhibiton extent was limited. According to current 
literature, this is the first study investigating the effects of integrin and ILK 
inhibitors on the regulation of smooth muscle contraction in the human 
prostate.  
 
BTT3033 is a sulfonamide derivative, and a specific inhibitor for α2β1 
integrin, binding to the α2I domain. In an in vitro assay assessing collagen I 
binding function, the EC50 of BTT3033 was 130 nM for α2β1, and 8-fold 
higher for α1β1, while no inhibition for other integrins was reported [129]. 
Considering the inhibitor was applied to tissue strips in the organ bath for 
this thesis, instead to cells in culture wells, 1 μM BTT3033 could be 







BOP is a dual inhibitor for integrins α4β1 and α9β1. Since the IC50 for α4β1 
and α9β1 is in the subnanomolar range [130], 1 μM BOP was assumed to 
effectively inhibit both α4β1 and α9β1.  
 
Cpd22 is a highly selective inhibitor for ILK, with an IC50 of 0.6 μM. In 
fact, EC50 values in ex vivo tissues may be higher than in cultured cells (or 
than IC50 values in biochemical assays), as the inhibitors have to penetrate 
interstitial space between cells and extracellular compartments, or have to 
cross similar barriers [77]. It is assumed that 3 μM Cpd22 mainly caused 
inhibition of ILK and to limited extent of Abl, CDK1 and p70S6K, so that 
the inhibition of the prostate smooth muscle was supposed to mainly due to 
ILK inhibition [131]. 
 
A crucial strategy to treat LUTS due to BPH, is to inhibit prostate smooth 
muscle contraction [100, 111]. Although the principal role of smooth 
muscle in the prostate is to squeeze the fluid from prostate glands into the 
urethra, which is mainly triggered by the neurogenic release of 
noradrenaline, it also compresses the urethra and causes voiding 
dysfunction in BPH patients. Reducing the basic tone of prostate smooth 





The basic tone is now believed to be regulated by not only neurogenic and 
adrenergic signals, but also by non-adrenergic mediators.  
 
Alpha1-blockers reduce neurogenic- and adrenergic-induced contraction. 
However, up to 69 % of patients are not satisfied by treatment with 
α1-blockers and still 36-45 % of patients are not satisfied even using a 
combination therapy of α1-blockers with 5-ARIs [22, 23, 77, 78]. On the 
one hand, in the human body, α1-blockers will bring a lack of reaction to 
the sympathetic nerve and possible unsatisfied sensation of ejaculation. On 
the other hand, in the course of urination, the vagus nerve is the one who 
dominates instead of the sympathetic nerve, which means neurogenic and 
adrenergic factors may contribute not so much as assumed in regulating 
basic tone, which may be the reason why merely targeting α1 receptor is 
not enough satisfying even combined with 5 ARIs [76, 79, 132]. 
 
Apart from α1-blockers, various receptors or kinases were shown to be 
involved in the prostate smooth muscle contraction, in addition to the well 
established and often characterized receptors and pathways, i. e. 
α1-adrenoceptors, calcium, PKC, and RhoA/ROCK. These pathways are at 
the same time (at least partially) shared by smooth muscle outside the 





if they are regarded as targets for male LUTS. Thus, the ideal targets for 
treating male LUTS should be relatively selective for smooth muscle, and 
only be located to the lower urinay tract system. The integrin family have a 
large diversity. Their functions suggest that integrins may have effects in a 
“cell- and integrin-type specific manner” [133]. Various isoforms of 
integrins are widely expressed and heterogeneously distributed in different 
organs. Consequently, organ-specific inhibition may be achieved by 
inhibitors for certain integrin types. Consequently, organ-specific integrin 
equipment, organ-specific integrin patterns, and organ-specific integrin 
inhibition may be achieved by inhibitors for certain integrin types. 
 
Integrins are responsible for cell adhesion, and have been widely 
investigated in different physiological and pathological processes like 
immune reaction and thrombosis, and some of them have been put into 
clinical or preclinical use [121]. For now, αIIbβ3 integrin in platelets has 
been proven as a clinically successful drug target for intervention of 
thrombosis after percutaneous coronary intervention, while medications 
addressing α4β1 and α4β7 integrins are reported to treat multiple sclerosis 
and inflammatory bowel disease [134]. Thus, integrins are in fact regarded 






Concerning contraction, integrins are essential mechanosensory receptors 
and β1-assembling integrins are among the most studied ones [133, 135, 
136]. This may offer promising approaches to attain prostate-specific 
inhibition of smooth muscle contraction, providing that integrins regulate 
contraction in prostate smooth muscle. Various β1 integrin heterodimers 
have been revealed to be involved in smooth muscle contraction in 
different organs, but not in the prostate yet. Studies showed that topical use 
of the inhibitor of fibronectin-binding integrin α5β1 facilitated relaxation of 
the airway, and blockage of laminin-binding integrin α7β1 reduced the 
contractile phenotype of airway smooth muscle cells [102, 124]. Another 
study reported that integrin α8β1 mediated the effects of milk fat globule 
epidermal growth factor-like 8 (Mfge8) on preventing IL-13-induced 
increases in airway contractility [137, 138]. Liu et al. reported that smooth 
muscle cell-specific deletion of integrin β1 reduced the ability of 
vasoconstriction [139]. Inhibition of α5β1 integrin has also been shown to 
decrease myogenic constriction using either inhibitors or antibodies 
[140-142]. It has also been found that knockdown of integrin β4 in vascular 
endothelial cells reduced sphingosylphosphorylcholine-induced vascular 
smooth muscle cells contractions [143]. Thus, the findings presented here 
for prostate smooth muscle are in line with those previous findings for 






According to research on expression profiles of more than 90% of all genes 
in 32 tissues and organs, integrin β1 is highly expressed in smooth muscle 
and the fragments per kilobase of transcript per million fragments mapped 
(FPKM) was 437.32, while the mean FPKM of integrin β1 among all tested 
tissue is 145.75 [144]. In that study, the FPKM of integrin β1 is 255.78 in 
bladder tissues and 163.44 in prostate tissues [144]. Its expression in the 
prostate was also suggested by Western blot and immunofluorescence in 
this study, but the role of integrin β1 or its integrins in the contraction of 
smooth muscle in the lower urinary tract system has to the best of my 
knowledge not been suggested before, and for the first time in this study. 
Among the β1 containing integrins, integrin α1β1, α2β1, α3β1, α6β1, α7β1, 
α10β1, α11β1 can be regarded as receptors for laminin and collagen and can 
mediate adhesion between cells to ECM [121]. Integrins α4β1and α9β1 can 
be bound by ligands like VCAM-1, osteopontin, ADAM and mediate 
adhesion between cells [121, 133]. In this study contraction measurements 
showed that the integrin α2β1 inhibitor BTT3033 inhibited prostate smooth 
muscle contraction, mainly on neurogenic and thromboxane-induced 
contractions, while the integrin α4β1/ α9β1 inhibitor BOP did not inhibit 
contractions. 
 
Apart from mediating adhesion mechanically, integrins serve to transmit 





integrin β cytoplasmic tail, is one of the kinases that interact with 
intracellular parts of integrins and process signals from the integrins [145], 
along with FAK, Src, and other kinases getting evolved in various 
regulations of cell functions. ILK, on the other hand, can reversely also 
influence the assembling and function of integrins. ILK is a 
serine/threonine kinase, which interacts with the intracellular part of 
integrin β1 and phosphorylates integrin β1 [146]. Like integrins, ILK has 
been associated with various roles in functions like adhesion, proliferation, 
apoptosis and motility [146] [147]. 
 
Integrin-linked kinase controls retinal angiogenesis [148], and mediates 
healing [149], platelet function [150, 151] and liver regeneration [152, 
153]. It was revealed that loss of ILK from mouse liver cells brought about 
apoptosis and hepatitis [154]. In the tumor research area, ILK turned out to 
be crucial in cancer formation and progression [146, 155]. ILK protein 
levels are increased in several human cancers and often the expression 
level predicts poor patient outcome [156]. ILK was found to be activated in 
acute myeloid leukemia [157], and it has been found that in multiple 
myeloma ILK is also a potential target [158]. 
 





actin accumulation [159]. Moreover, ILK was found to play roles in 
cardiomyocytes and in cardiac smooth muscle [156]. Studies regarding the 
heart showed that ILK mediates development and contraction of the heart 
[82] and gets involved in cardiac hypertrophy, pulmonary hypertension or 
other diseases [160, 161]. Studies also found that ILK regulates smooth 
muscle contraction in gut and may be involved in pulmonary hypertension 
[162]. However, to the best of my knowledge, ILK has not been 
investigated in smooth muscle contraction of the prostate yet either. Here, 
the ILK inhibitor Cpd22 showed inhibition effects on prostate smooth 
muscle contraction, mainly on neurogenic and thromboxane-induced 
contractions. 
 
The results of Western blot and immunofluorescence in this thesis suggest 
that ILK1 and integrin subunits α2 and β1 are expressed in the prostate 
stroma as they colocalize with the smooth muscle marker caponin. In 
addition, α4 and α9 was also expressed in the prostate stroma. However, the 
dual integrin α4β1/ α9β1 inhibitor BOP had no effect on contraction in this 
study. Consequently, results suggesting expression must not necessarily 
guarantee a function in the field of contraction.  Testing the ex vivo 
effects of inhibitors in the organ bath can provide direct evidence of 






The functions of integrins and ILK profoundly rely on cell-cell and 







[164-166], which can not be mimicked precisely in cell culture. Although 
efforts have been made through adjusting ion concentration and alteration 
to 3D culture, contraction studies in organ bath are still more close to the 
natural condition, with the results more intuitive and direct. Thus, although 
cell culture studies can also indicate contractility using contraction assays, 
findings and conditions may be less physiological than those using ex vivo 
tissues or in vivo studies.  
 
Human prostate tissues from radical prostatectomy used here were taken 
from the periurethral zone, where tumors are rare. Although the most ideal 
tissue for studies like this would be from BPH patients, surgeries handling 
BPH (i.e. ablative approaches) destroy and heat the tissue. Thus, tissues 
would be traumatized and can not serve to be investigated by contraction 
assay and molecular studies anymore. Animal prostate tissues are 
commonly used in organ baths for contraction assay. However, the 
findings in animal models can not always be reproduced in studies using 
human tissues. Taking detrusor as examples, studies showed that 
ATP-purinergic contraction in an important part of sympathetic nerve 
mediated contraction, however, there has never been a study indicating 





prostate [167].  
 
Human prostate tissues show high heterogeneity among individuals. This 
can be seen from the wide error bars of contraction assays using human 
prostate compared with those using animal model. In this study, the high 
individual variation is also well reflected by Western blot analyses 
showing very high heterogeneity of calponin and pan-cytokeratin 
expression levels, which refers to the heterogeneity of smooth muscle and 
glandular composition, and diverging degree of BPH (as shown by the 
varying content of PSA). Although this may also result from sampling, 
experimental design should avoid the influence of heterogeneity. 
Consequently, four pieces of prostate tissue from the same patient were 
allocated to 2 groups in each set of experiment to avoid individual 
differences. Secondly, contractions were expressed as % of high molar 
KCl-induced contraction to avoid heterogeneity resulting from individual 
variation from sampling, or from different content and condition of smooth 
muscle, or from different sample sizes. 
 
BTT3033 and Cpd22 showed clear inhibition of neurogenic, and 
thromboxane A2-induced contractions. Only very slight inhibitions were 





well, which may be neglectable, as the extent of any inhibition was very 
small and data for different α1-adrenergic agonists were partially 
inconclusive. Interestingly, BTT3033 and Cpd22 showed the same pattern 
of contraction inhibition. Instead of considering those differences as 
coincidence or randomity, a better explanation is that integrins /ILK may 
regulate prostate smooth muscle in concert, and different from the current 
mainstream signaling pathway.  
 
BTT3033 and Cpd22 showed different results on U46619- and 
endothelin-1-induced contractions, although these are both non-adrenergic 
agonists. The reason may be differences at the two different receptors they 
bind. U46619 and endothelin-1 activate the thromboxane A2 receptor and 
endothelin receptors, respectively. Both are G protein-coupled receptors, 
however, the former has been supposed to couple predominately with 
Gα12/13, and endothelin-receptors predominately with Gαq/11 [168, 169]. 
According to current studies, Gαq/11 activates phospholipase Cβ (PLCβ), 
and mediates contraction mostly via Ca
2+
- and PCK-dependent pathway, 
while Gα12/13 may further activate the guanine nucleotide exchange factor 
p115 RhoGEF (GEF) and mediates contraction in a Ca
2+
-independent, but 
RhoA/Rock-dependent pathway [169, 170]. Notably, it has been reported 
that ILK is responsible for Ca
2+
 independent vascular smooth muscle 





insensitive to the MLCK inhibitor AV25 [171, 172]. According to the 
theory of the publications above, endothelin-1 mainly induces 
Ca
2+
-dependent MLCK activation, and is relatively resistant to ILK 
inhibition, considering MLCK/MLCP activity ratio is crucial. However, 
U46619 mainly induces contraction via Ca
2+
 independent MLCP 
deactivation, so that the ILK/MLCP activity ratio may be a more crucial 
factor and sensible to Cpd22. However, not many studies supported or 
tried to disprove it. A study performed with human prostate smooth muscle 
showed that U46619 may induce prostate smooth muscle contraction via 
both Ca
2+
-dependent and -independent pathways [109]. This study is more 
in line with the formers, and may further indicate the possibility that 
integrins like integrin α2β1 mediate smooth muscle contraction via ILK.  
 
Noradrenaline, methoxamine, and phenylephrine activate the same 
receptor, namely α1-adrenoceptors, so that the divergent effects of 
BTT3033 and Cpd22 on noradrenaline- and methoxamine-induced 
contractions on the one hand, and phenylephrine-induced contractions on 
the other hand, is harder to explain, although our findings are conclusive to 
that effect, that any effect of BTT-3033 and Cpd22 on α1-adrenergic 
contractions is very small, if occuring at all. However, divergent 
pharmacological profiles of these α1-adrenergic agonists may be still worth 





neurotransmitter release on rat superior cervical ganglion cells, 
phenylephrine but not methoxamine will increase fractional noradrenaline 
efflux, which can not be blocked by α1-adrenergic receptor antagonists or 
by removal of extracellular calcium [20, 173]. Besides, methoxamine can 
bind to α1b-adrenoceptors, while noradrenaline and phenylephrine can not 
[60]. Certainly, two divergent results for phenylephrine and other 
α1-adrenergic agonists show that the mechanism of regulation of smooth 
muscle contraction are much more complicated than currently illustrated 
and needs to be further revealed [76].  
 
Alpha1-blockers only inhibit neurogenic and α1-adrenergic contractions, 
but not others. New options are expected to target also non-adrenergic 
contractions. The effect of PDE inhibitors cover the non-adrenergic 
contractions, but provide efficacy that is not satisfying enough [80]. The 
inhibitors in this study were able to reduce not only neurogenic but also 
non-adrenergic thromboxane A2-induced contractions, which have a 
different spectrum of contraction inhibition than the current α1-blockers. 
 
Some of the integrins that have not been investigated in this and current 
studies may also be involved in prostate smooth muscle contraction. 





function, the special integrin barcode may be found with a specific role in 
prostate smooth muscle contraction, or with limited side effects outside the 
lower urinary tract from their inhibitors. More studies may be needed to 
explore various integrins and their effect and specificity in the prostate 
smooth muscle contraction.  
 
Taken together, this study revealed possible roles of integrin α2β1 and ILK 
in prostate smooth muscle contraction. The inhibitors for them, i.e. 
BTT3033 and Cpd22 reduce contractions simulated by EFS, as well as by 
the non-adrenergic agonist U46619. Their effects of contraction induced 
by the adrenergic receptor agonists noradrenaline and methoxamine are 
weak, although significant. They provide a different spectrum of 
contraction inhibition than α1-blockers. The consistency of the inhibition 
pattern between BTT3033 and Cpd22 suggests the possibility that integrin 
α2β1 mediates contraction via ILK. Integrins and ILK may serve as novel 
target for treating LUTS suggestive of BPH in vivo. Further studies are 
expected to investigate the roles of other integrins in the prostate smooth 
muscle contractions and their specificities, as well as the underlying 
mechanisms.  
 
Non-adrenergic mediators including thromboxane A2 are suspected to 





treatment with α1-blockers, what may account for the limited efficacy of 
α1-blockers. Compounds inhibiting prostate smooth muscle contraction in 
vitro may be principally considered as promising candidates for in vivo 
studies, as it may be expected that the inhibition of smooth muscle 
contraction translates to improvements of LUTS. However, the inhibition 
of adrenergic contractions observed in our study was small and is probably 
neglectable in vivo, in contrast to the clear inhibitions of EFS- and 
U46619-induced contractions. Certainly, the contribution of integrins and 
ILK to urodynamic regulation can not be estimated until in vivo studies are 
performed. However, various cardiovascular side effects could limit the 
use of BTT-3033 or Cpd22 for LUTS treatment. Alpha2beta1 integrin 
occurs at different sites in the cardiovascular system. Apart from 
endothelial and vasuclar smooth muscle cells, it forms a major collagen 
binding receptor of platelets, also referred to as glycoprotein Ia/IIa, which 
accounts for platelet adhesion to injured sites at the vessel wall [174, 175]. 
Consequently, α2β1 critically regulates hemostasis, and promotes 
thrombus formation and increases the risk of myocardial infarction and 
stroke [176]. On the other hand, its underexpression is associated with only 
mildly increased bleeding times but not with severe bleeding, and allows 
quite normal hemostasis [176]. Accordingly, small molecule α2β1 
inhibitors, which were tested as antithrombotic intervention in animal 





Hemodynamic effects may be rather expected from ILK inhibitors, than 
from integrin α2β1 inhibition. Thus, in vivo administration of Cpd22 
decreased the heart rate and pulmonary vascular resistance [161]. 
Although no effect on mean arterial pressure was reported, hypotensive 
side effects still need to be examined, as effects on peripheral or systemic 








Small molecule inhibitors for integrins α2β1 and ILK cause inhibition of 
neurogenic and thromboxane A2-induced smooth muscle contractions in 
the human prostate. Inhibition of integrins and ILK to target prostate 








Male LUTS cause heavy burdens, and are commonly attributed to BPH. 
Prostate smooth muscle tone increases in BPH and often accounts for 
bladder outlet obstruction, causing the symptoms. Reducing the prostate 
smooth muscle tone is a crucial strategy for medical LUTS treatment. In 
the current medical therapy, α1-blockers are the first option, considering 
the crucial role of α1-adrenoceptors in mediating prostate smooth muscle 
contraction. However, non-adrenergic contraction of prostate smooth 
muscle is not within the α1-blockers’ spectrum and probably accounts for 
their limited efficacy. 
 
Integrins are responsible for cell adhesion, anchoring the cell skeleton to 
other cells or to extra-cellular matrix, what is crucial for smooth muscle 
contraction. Integrins mediate cell functions through partners like ILK. 
Integrins and ILK have been shown to be involved in smooth muscle 
contraction in different body systems. However, according to current 
available literature, they have never been investigated in prostate smooth 






The integrin α2β1 inhibitor BTT3033, the integrin α4β1/α9β1 inhibitor BOP 
and the ILK inhibitor Cpd22 were investigated in the present study. 
Western blot and immunofluorescence suggested that all related integrin 
subunits may be expressed in the human prostate, and that they are located 
to stromal smooth cells. Contraction experiments showed that BTT3033 
and Cpd22, but not the integrin α4β1/α9β1 inhibitor BOP inhibit 
contractions of human prostate tissues. BTT3033 and Cpd22 shared the 
same pattern, as they both inhibited prostate smooth muscle contractions 
induced by the EFS-stimulated neurotransmission and non-adrenergic 
agonist U46619, with no or very limited inhibition effects on contractions 
induced by the α1-adrenergic agonists noradrenaline, methoxamine, and 
phenylephrine, as well as non-adrenergic agonist endothelin-1. 
 
To the best of my knowledge, this is the first study adressing the effects of 
integrin and ILK inhibitors on prostate smooth muscle contraction, and 
suggesting a role of integrins and ILK in human prostate smooth muscle 
contraction. As integrins show organ-specific composition, integrin 
inhibitors targeting a prostate-specific integrin code may offer a promising 
alternative or supplementary approach to attain prostate specific inhibition, 







α1-blockers α1-adrenoceptor antagonists 
β3-agonists β3-adrenoceptor agonists 
5-ARIs 5α-reductase inhibitors 
AC Adenylyl cyclases 
ANOVA One-way analysis of variance 
Arf ADP ribosylation factor 
ATP Adenosine 5’-triphosphate 
AUR Acute urinary retention 
BOO Bladder outlet obstruction 
BPE Benign prostatic enlargement 
BPH Benign prostatic hyperplasia 
BPO Benign prostatic obstruction 
CaCl2•2H2O Calcium chloride dihydrate 
CaM Calmodulin 
cAMP Adenosine 3':5'-cyclic monophosphate 





Cdc42 Cell division cycle 42 
cGMP Guanosine 3', 5'-cyclic monophosphate  
COX Cyclooxygenase 
CUR Chronic urinary retention 
DAG Diacylglycerol 
DAPI 4’, 6’-diamidino-2-phenylindole-dihydrochloride 
DHT Dihydrotestosterone 
DMSO Dimethyl sulfoxide 
EAU European Association of Urology 
EC50 Half maximal effective concentration 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
EFS Electric field stimulation 
EPAC Exchange proteins directly activated by cAMP 
FAK Focal adhesion kinase 
FRKM Fragments per kilobase of exon model per million reads  
 mapped 
GEFs Guanine nucleotide exchange factors 





IC50 Half maximal inhibitory concentration 
ILK Integrin-linked kinase 
IP3 Inositol 1,4,5-trisphosphate 
IPSS International Prostate Symptom Score 
KCl Potassium chloride 
K-H Krebs- Henseleit            
KH2PO4 Potassium hydrogen phosphate 
LUTS Lower urinary tract symptoms 
MAPK Mitogen-activated protein kinase 
Mfge8 Milk fat globule epidermal growth factor-like 8 
MgCl2 Magnesium chloride  
MgSO4•7H2O Magnesium sulfate heptahydrate  
MAPKs Mitogen-activated protein kinase 
MLC Myosin light chain 
MLCK MLC kinase 
MVD Microvessel density 
NaCl Sodium chloride 






NPY Neuropeptide Y 
OCT Optimal cutting temperature 
PAK P21-Activated Kinase 
PBS Phosphate-buffered saline 
PBS-T Phosphate-buffered saline with 0.1% Tween 20 
PDE Phosphodiesterase 
PGs prostaglandins 
PKA Protein kinase A 
PKC Protein kinase C 
PLCβ  Phospholipase Cβ 
PKG Protein kinase G 
PLK Polo-like kinase 
PPADS Pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate 
PSA Prostate-specific antigen 
PTK Protein tyrosine kinases 
Qmax The maximum flow rate 
QOL Quality of life 
Rac Ras-related C3 botulinum toxin substrate 





Ran Ras-related Nuclear protein 
Rho Rhodopsin 
RhoGEF Rho guanine nucleotide exchange factor  
SD Standard deviation 
TXA2 Thromboxane A2 (TXA2) 
UR Urinary retention 
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